Convergence Investment Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.32M | Sell |
19,873
-172
| -0.9% | -$38.2K | 0.71% | 41 |
|
|
2025
Q4 | $4.58M | Sell |
20,045
-7,590
| -27% | -$1.73M | 0.91% | 26 |
|
|
2025
Q3 | $6.4M | Buy |
27,635
+2,848
| +11% | +$580K | 1.44% | 10 |
|
|
2025
Q2 | $4.6M | Sell |
24,787
-2,579
| -9% | -$479K | 1.17% | 17 |
|
|
2025
Q1 | $5.73M | Sell |
27,366
-3,883
| -12% | -$755K | 1.59% | 10 |
|
|
2024
Q4 | $5.55M | Buy |
31,249
+1,402
| +5% | +$258K | 1.24% | 13 |
|
|
2024
Q3 | $5.89M | Buy |
29,847
+534
| +2% | +$99.7K | 1.59% | 11 |
|
|
2024
Q2 | $5.03M | Buy |
29,313
+5,193
| +22% | +$860K | 1.47% | 11 |
|
|
2024
Q1 | $4.39M | Buy |
24,120
+1,105
| +5% | +$190K | 1.68% | 8 |
|
|
2023
Q4 | $3.57M | Sell |
23,015
-654
| -3% | -$95.3K | 1.86% | 8 |
|
|
2023
Q3 | $3.53M | Sell |
23,669
-87
| -0.4% | -$12.8K | 2.09% | 7 |
|
|
2023
Q2 | $3.2M | Sell |
23,756
-302
| -1% | -$44.3K | 1.84% | 8 |
|
|
2023
Q1 | $3.83M | Sell |
24,058
-337
| -1% | -$51.5K | 2.26% | 6 |
|
|
2022
Q4 | $3.94M | Buy |
24,395
+290
| +1% | +$44.5K | 2.34% | 4 |
|
|
2022
Q3 | $3.23M | Sell |
24,105
-226
| -0.9% | -$32.4K | 2.11% | 4 |
|
|
2022
Q2 | $3.73M | Buy |
24,331
+543
| +2% | +$83K | 2.25% | 3 |
|
|
2022
Q1 | $3.86M | Buy |
23,788
+535
| +2% | +$77.7K | 1.99% | 3 |
|
|
2021
Q4 | $3.15M | Buy |
23,253
+2,822
| +14% | +$333K | 1.6% | 8 |
|
|
2021
Q3 | $2.2M | Sell |
20,431
-8,320
| -29% | -$951K | 1.18% | 19 |
|
|
2021
Q2 | $3.24M | Buy |
28,751
+2,542
| +10% | +$286K | 1.39% | 11 |
|
|
2021
Q1 | $2.84M | Sell |
26,209
-1,336
| -5% | -$143K | 1.3% | 14 |
|
|
2020
Q4 | $2.95M | Sell |
27,545
-18,124
| -40% | -$1.74M | 1.49% | 14 |
|
|
2020
Q3 | $4M | Sell |
45,669
-9,602
| -17% | -$904K | 1.39% | 10 |
|
|
2020
Q2 | $5.43M | Buy |
55,271
+2,487
| +5% | +$219K | 1.87% | 4 |
|
|
2020
Q1 | $4.02M | Sell |
52,784
-2,837
| -5% | -$242K | 1.76% | 8 |
|
|
2019
Q4 | $4.92M | Sell |
55,621
-4,794
| -8% | -$398K | 1.4% | 10 |
|
|
2019
Q3 | $4.58M | Sell |
60,415
-3,126
| -5% | -$214K | 1.27% | 12 |
|
|
2019
Q2 | $4.62M | Sell |
63,541
-5,117
| -7% | -$402K | 1.12% | 14 |
|
|
2019
Q1 | $5.53M | Sell |
68,658
-3,060
| -4% | -$250K | 1.21% | 10 |
|
|
2018
Q4 | $6.61M | Buy |
71,718
+4,542
| +7% | +$399K | 1.52% | 5 |
|
|
2018
Q3 | $6.35M | Sell |
67,176
-36,301
| -35% | -$3.44M | 1.3% | 7 |
|
|
2018
Q2 | $9.59M | Buy |
103,477
+2,497
| +2% | +$244K | 1.34% | 7 |
|
|
2018
Q1 | $9.56M | Sell |
100,980
-12,563
| -11% | -$1.38M | 1.25% | 6 |
|
|
2017
Q4 | $11M | Buy |
113,543
+6,810
| +6% | +$642K | 1.47% | 4 |
|
|
2017
Q3 | $9.48M | Buy |
106,733
+6,438
| +6% | +$490K | 1.34% | 3 |
|
|
2017
Q2 | $7.27M | Sell |
100,295
-16,690
| -14% | -$1.12M | 1.06% | 6 |
|
|
2017
Q1 | $7.62M | Sell |
116,985
-349
| -0.3% | -$21.9K | 1.07% | 6 |
|
|
2016
Q4 | $7.35M | Buy |
117,334
+22,981
| +24% | +$1.4M | 1.01% | 6 |
|
|
2016
Q3 | $5.95M | Sell |
94,353
-17,523
| -16% | -$1.13M | 0.88% | 13 |
|
|
2016
Q2 | $6.93M | Sell |
111,876
-49,339
| -31% | -$3.01M | 0.95% | 10 |
|
|
2016
Q1 | $9.21M | Sell |
161,215
-1,057
| -0.7% | -$58.9K | 1.1% | 7 |
|
|
2015
Q4 | $9.61M | Buy |
+162,272
| New | +$9.35M | 1.08% | 11 |
|
|
2014
Q2 | – | Sell |
-62,576
| Closed | -$3.22M | – | 365 |
|
|
2014
Q1 | $3.22M | Buy |
62,576
+51,450
| +462% | +$2.6M | 0.49% | 49 |
|
|
2013
Q4 | $588K | Buy |
11,126
+1,656
| +17% | +$81.4K | 0.1% | 248 |
|
|
2013
Q3 | $424K | Buy |
9,470
+2,243
| +31% | +$99.4K | 0.09% | 210 |
|
|
2013
Q2 | $299K | Buy |
+7,227
| New | +$316K | 0.08% | 258 |
|
Other funds holding ABBV
VCM
VPM
Convergence Investment Partners's ABBV Position: Q1 2026 in Review
Convergence Investment Partners reduced its AbbVie (ABBV) stake by 0.86% in Q1 2026, selling an estimated $38.2K and leaving 19,873 shares worth $4.32M. The position accounts for 0.71% of the portfolio, ranked #41.
Convergence Investment Partners first reported a position in ABBV in Q2 2013 and has held it in 46 quarters since. The position peaked at $11M in Q4 2017. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Convergence Investment Partners held 19,873 shares of AbbVie worth $4.32M as of Q1 2026.
- Convergence Investment Partners sold 172 AbbVie shares in Q1 2026, an estimated $38.2K.
- AbbVie made up 0.71% of Convergence Investment Partners's portfolio in Q1 2026, its #41 holding.
- Convergence Investment Partners first reported a position in AbbVie in Q2 2013 and has held it in 46 quarters since.
- Convergence Investment Partners's AbbVie position peaked at $11M in Q4 2017.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Convergence Investment Partners's 13F filing for Q1 2026, filed 7 May 2026.